Skip to content

Celldex Therapeutics CLDX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-18,587.7%-15,809pp-2,778.9%-534pp-2,245.3%+2,644pp-4,889%-3,358pp
Net margin-16,737.2%-14,488pp-2,248.8%-194pp-2,054.8%+2,711pp-4,765.6%-3,250pp
Returns
Return on equity-40.6%-13.8pp-26.8%+10.6pp-37.4%-7.3pp-30.1%-7.7pp
Return on invested capital-47%-12.1pp-34.9%+9.4pp-44.3%-10.6pp-33.7%-7.9pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×
Liquidity
Current ratio10.5×-8.4×18.9×+5.0×13.9×-3.2×17.1×-7.8×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Per Share
Book value per share$7.94-31.6%$11.60+31.0%$8.86+27.3%$6.96-28.9%
Valuation
Market capitalization$1.8B+7.6%$1.68B-22.7%$2.17B+3.3%$2.1B+16.4%
Price / sales1,167.4×+929×238.8×-76.3×315.1×-576×890.6×+503×
Price / book3.4×+1.2×2.2×-2.8×5.1×-1.4×6.4×+2.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Celldex Therapeutics's ratios come from?
Every ratio is computed from Celldex Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.